首页
学术期刊
论文检测
AIGC检测
热点
更多
数据
THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF CHLORPROPAMIDE
被引:2
|
作者
:
KALLIO, J
论文数:
0
引用数:
0
h-index:
0
机构:
Departments of Pharmacology and Clinical Pharmacology, University of Turku
KALLIO, J
HUUPPONEN, R
论文数:
0
引用数:
0
h-index:
0
机构:
Departments of Pharmacology and Clinical Pharmacology, University of Turku
HUUPPONEN, R
PYYKKO, K
论文数:
0
引用数:
0
h-index:
0
机构:
Departments of Pharmacology and Clinical Pharmacology, University of Turku
PYYKKO, K
机构
:
[1]
Departments of Pharmacology and Clinical Pharmacology, University of Turku
来源
:
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
|
1990年
/ 39卷
/ 01期
关键词
:
Chlorpropamide;
Debrisoquine phenotype;
Metabolism;
Pharmacogenetics;
Pharmacokinetics;
D O I
:
10.1007/BF02657068
中图分类号
:
R9 [药学];
学科分类号
:
1007 ;
摘要
:
The pharmacokinetics and urinary metabolite pattern of a single oral dose of chlorpropamide 250 mg have been studied in 6 extensive and 5 poor metabolizers of debrisoquine. Ammonium chloride was given orally to acidify the urine in order to make elimination of the parent drug dependent on metabolism alone. The concentration profile in serum and the pharmacokinetic parameters of the parent drug were similar in both groups. However, the ratio in urine of unchanged chlorpropamide to its hydroxylated metabolites was higher in poor than in extensive metabolizers. © 1990 Springer-Verlag.
引用
收藏
页码:93 / 95
页数:3
相关论文
共 50 条
[1]
THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PROPRANOLOL
LENNARD, MS
论文数:
0
引用数:
0
h-index:
0
LENNARD, MS
JACKSON, PR
论文数:
0
引用数:
0
h-index:
0
JACKSON, PR
FREESTONE, S
论文数:
0
引用数:
0
h-index:
0
FREESTONE, S
TUCKER, GT
论文数:
0
引用数:
0
h-index:
0
TUCKER, GT
RAMSAY, LE
论文数:
0
引用数:
0
h-index:
0
RAMSAY, LE
WOODS, HF
论文数:
0
引用数:
0
h-index:
0
WOODS, HF
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,
1984,
17
(06)
: 679
-
685
[2]
LACK OF RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF QUININE
WANWIMOLRUK, S
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND
UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND
WANWIMOLRUK, S
CHALCROFT, S
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND
UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND
CHALCROFT, S
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,
1991,
32
(05)
: 617
-
620
[3]
PHARMACOKINETICS AND PHARMACODYNAMICS OF NIFEDIPINE AND DEBRISOQUINE OXIDATION PHENOTYPE
LEWIS, RV
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT THERAPEUT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT THERAPEUT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
LEWIS, RV
JACKSON, PR
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT THERAPEUT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT THERAPEUT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
JACKSON, PR
RAMSAY, LE
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT THERAPEUT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT THERAPEUT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
RAMSAY, LE
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,
1985,
19
(04)
: P562
-
P562
[4]
LACK OF RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS AND 1ST DOSE EFFECT OF PRAZOSIN
LENNARD, MS
论文数:
0
引用数:
0
h-index:
0
机构:
CLATTERBRIDGE HOSP, HYPERTENS UNIT, WIRRAL, MERSEYSIDE, ENGLAND
CLATTERBRIDGE HOSP, HYPERTENS UNIT, WIRRAL, MERSEYSIDE, ENGLAND
LENNARD, MS
MCGOURTY, JC
论文数:
0
引用数:
0
h-index:
0
机构:
CLATTERBRIDGE HOSP, HYPERTENS UNIT, WIRRAL, MERSEYSIDE, ENGLAND
CLATTERBRIDGE HOSP, HYPERTENS UNIT, WIRRAL, MERSEYSIDE, ENGLAND
MCGOURTY, JC
SILAS, JH
论文数:
0
引用数:
0
h-index:
0
机构:
CLATTERBRIDGE HOSP, HYPERTENS UNIT, WIRRAL, MERSEYSIDE, ENGLAND
CLATTERBRIDGE HOSP, HYPERTENS UNIT, WIRRAL, MERSEYSIDE, ENGLAND
SILAS, JH
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,
1988,
25
(02)
: 276
-
278
[5]
LACK OF RELATIONSHIP BETWEEN TOLBUTAMIDE METABOLISM AND DEBRISOQUINE OXIDATION PHENOTYPE
PEART, GF
论文数:
0
引用数:
0
h-index:
0
机构:
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
PEART, GF
BOUTAGY, J
论文数:
0
引用数:
0
h-index:
0
机构:
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
BOUTAGY, J
SHENFIELD, GM
论文数:
0
引用数:
0
h-index:
0
机构:
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
SHENFIELD, GM
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,
1987,
33
(04)
: 397
-
402
[6]
LACK OF RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE KINETICS OF TOLBUTAMIDE
SHENFIELD, GM
论文数:
0
引用数:
0
h-index:
0
机构:
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
SHENFIELD, GM
BOUTAGY, J
论文数:
0
引用数:
0
h-index:
0
机构:
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
BOUTAGY, J
PEART, GFD
论文数:
0
引用数:
0
h-index:
0
机构:
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
PEART, GFD
ACTA PHARMACOLOGICA ET TOXICOLOGICA,
1986,
59
: 116
-
116
[7]
Relationship between debrisoquine oxidation phenotype and susceptibility to lung cancer
Sardas, S
论文数:
0
引用数:
0
h-index:
0
机构:
Gazi Univ, Fac Pharmacol, Dept Toxicol, Ankara, Turkey
Gazi Univ, Fac Pharmacol, Dept Toxicol, Ankara, Turkey
Sardas, S
Cok, I
论文数:
0
引用数:
0
h-index:
0
机构:
Gazi Univ, Fac Pharmacol, Dept Toxicol, Ankara, Turkey
Gazi Univ, Fac Pharmacol, Dept Toxicol, Ankara, Turkey
Cok, I
TOXICOLOGY,
2001,
164
(1-3)
: 153
-
153
[8]
OXIDATION PHENOTYPE - COMPARISON BETWEEN DEBRISOQUINE AND DEXTROMETHORPHAN TESTS
VINCENTVIRY, M
论文数:
0
引用数:
0
h-index:
0
机构:
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
VINCENTVIRY, M
RICHE, I
论文数:
0
引用数:
0
h-index:
0
机构:
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
RICHE, I
SIEST, G
论文数:
0
引用数:
0
h-index:
0
机构:
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
SIEST, G
GALTEAU, MM
论文数:
0
引用数:
0
h-index:
0
机构:
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
LAB CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE
GALTEAU, MM
CLINICAL CHEMISTRY,
1989,
35
(06)
: 1184
-
1185
[9]
DIGOXIN PHARMACOKINETICS AND DEBRISOQUINE METABOLIC PHENOTYPE
HOU, ZY
论文数:
0
引用数:
0
h-index:
0
机构:
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
HOU, ZY
MEYER, PS
论文数:
0
引用数:
0
h-index:
0
机构:
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
MEYER, PS
SOLDIN, S
论文数:
0
引用数:
0
h-index:
0
机构:
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
SOLDIN, S
SCHWARTZ, SL
论文数:
0
引用数:
0
h-index:
0
机构:
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
SCHWARTZ, SL
WOOSLEY, RL
论文数:
0
引用数:
0
h-index:
0
机构:
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC
WOOSLEY, RL
CLINICAL PHARMACOLOGY & THERAPEUTICS,
1991,
49
(02)
: 126
-
126
[10]
STEREOSELECTIVE METABOLISM OF METOPROLOL IN CAUCASIANS AND NIGERIANS - RELATIONSHIP TO DEBRISOQUINE OXIDATION PHENOTYPE
LENNARD, MS
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV COLL HOSP IBADAN,DEPT MED,IBADAN,NIGERIA
LENNARD, MS
TUCKER, GT
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV COLL HOSP IBADAN,DEPT MED,IBADAN,NIGERIA
TUCKER, GT
WOODS, HF
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV COLL HOSP IBADAN,DEPT MED,IBADAN,NIGERIA
WOODS, HF
SILAS, JH
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV COLL HOSP IBADAN,DEPT MED,IBADAN,NIGERIA
SILAS, JH
IYUN, AO
论文数:
0
引用数:
0
h-index:
0
机构:
UNIV COLL HOSP IBADAN,DEPT MED,IBADAN,NIGERIA
IYUN, AO
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,
1989,
27
(05)
: 613
-
616
←
1
2
3
4
5
→